Acasti Pharma Gets Principal Investigator for CaPre Phase 3 Program

Acasti Pharma (NASDAQ:ACST; TSXV:ACST) announced Dr. Dariush Mozaffarian will serve as the principal investigator to oversee the phase 3 development program of CaPre.
As quoted in the press release:

Dr. Mozaffarian is a renowned researcher whose widely published work focuses on how diets such as those rich in omega-3s and lifestyle can influence cardiometabolic health.
“As demonstrated in the Phase 2 clinical trials, CaPre reduces harmful triglycerides and non-HDL cholesterol in the blood, and may also increase levels of HDL-C (good cholesterol) without increasing LDL-C (bad cholesterol). Patients with severe hypertriglyceridemia are at greater risk of cardiovascular disease and pancreatitis, and the field could greatly benefit from a treatment that reduces elevated triglycerides while at the same time positively modulating the other major lipids associated with cardiovascular disease risk,” said Dr. Mozaffarian, the Jean Mayer Professor of Nutrition and Medicine, and the Dean of the Friedman School of Nutrition Science and Policy at Tufts University. “CaPre is the first omega-3 phospholipid ester to be investigated for the treatment of severe hypertriglyceridemia and may become a valuable therapeutic option for treating this condition.”

Click here to read the full press release.

Source: www.marketwired.com